Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Research

| More

Maintain Reduce on Dr. Reddy's Labs - Valuations leave little room for disappointment - HDFC Securities

Posted On: 2020-05-21 14:27:01


Ms. Bansi Desai, Institutional Research Analyst, HDFC Securities.

Dr. Reddy's Labs (Q4FY20 Results Review): Valuations leave little room for disappointment. Maintain Reduce.
(TP Rs 3, 770, CMP Rs 3, 910, MCap Rs 650 bn)

Dr. Reddys' Q4 PAT came ahead of expectations led by strong revenue growth (+15% YoY, 6% beat) and tax write back. EBIDTA margins came in line as lower gross margins were offset by lower SG&A spends. Improved growth trajectory and cost control initiatives have led to EBIDTA margin expansion (~300bps) over the last three years. Going forward, while we continue to factor cost savings, a large part (~20%) of our FY22 estimates hinges on key product approvals in the US (gNuvaring, gCopaxone), the approval timelines for which remain uncertain. Despite factoring these launches and margin expansion as per company guidance, we don't see upside from current levels. The stock trades at 27x/21x FY21/22 EPS which leaves limited room for execution miss. We maintain Reduce rating with a revised TP of Rs3,770 based on 20x FY22 EPS.

Revenue beat, margins in line: Revenues grew at 15% YoY at Rs44.3bn as strong growth in US (+13% YoY, new launches, higher volumes), Europe (+80% YoY, +11% YoY, strong performance in Germany, new markets) offset muted growth in India (+5%YoY, logistics impact). EBIDTA margins came at 21.6% (down 216bps QoQ) as lower gross margins (adverse business mix, write offs) were partially offset by lower SG&A spend (-120bps QoQ).

Major part of US growth hinges on two key product approvals: We forecast the US business to register 14% revenue CAGR over the next two years and two key assets - gNuvaring and gCopaxone account for ~50%+ of growth in the same period. We factor these high value launches, along with sustained cost savings and factor ~350bps margin expansion over FY20-22e. Any delay in approval/launch timelines will impact our estimates.

Key call takeaways: a) Price erosion in US has stabilized, deflation to continue; b) gNuvaring and gCopaxone - CRL to be filed in few months; gVascepa - no hurdles on regulatory front; expects to launch 25 products in the US; c) Wockhardt deal closure expected in Q1FY21; d) Covid impact was neutral on revenues; e) Guidance: Gross margin: 52-54% of sales, R&D spend: 9-10% of sales, Capex: Rs10bn in FY21, Tax rate: 22%

Maintain Reduce, risks: We increase our EPS estimates by 3-7% for FY21/22 and revise our TP to Rs3,770 (from Rs3,330 earlier). Our TP is based on 20x FY22 EPS. Key upside risks: Lower price erosion in the US, higher growth in India and EM markets; faster than expected approvals for key products in the US.

Shares of DR.REDDY's LABORATORIES LTD. was last trading in BSE at Rs.3910.75 as compared to the previous close of Rs. 3699.55. The total number of shares traded during the day was 137220 in over 12937 trades.

The stock hit an intraday high of Rs. 3927.8 and intraday low of 3695.1. The net turnover during the day was Rs. 524998706.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Rollover Report for September 2020 - October 2020: Angel Broking

Covid Recovery Pulse - Sep 25, 2020 - ICICI Securities

Quick Comment - Suven Pharmaceuticals - ICICI Securities

Derivatives Strategy - Sep 25, 2020 - Positional Option - ICICI Securities

Gladiator Stocks - Ramco Cement - ICICI Securities

IPO Review - UTI Asset Management Company - ICICI Securities

Stock of the Day - Zensar Technologies - Sep 25, 2020 - Angel Broking

Accenture Q4FY2020 Result - Angel Broking

Granules India receives ANDA approval - Angel Broking

Zydus Cadila receives US FDA approval - Angel Broking

Cipla - ANDA approval - Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd

Mindspace REIT - Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd

UTI AMC - IPO - Mr. Jaikishan Parmar - Sr. Equity Research Analyst, Angel Broking Ltd

Balkrishna Industries - Growth momentum continues - ICICI Securities

Rollover Analysis (September 25): Nifty starts October series with low OI amid high volatility

Derivatives View (September 25): Sell Bank Nifty in range of 20650-20750 - ICICI Securities

Rollover Analysis - Sept 20: Selling climax on expiry as markets crumble - YES Securities

Zydus Wellness - Leadership in niche categories; initiate at BUY - ICICI Securities

Power - Setting the stage - ICICI Securities

Company Update - Elgi Equipments - ICICI Securities

Nano Nivesh - The Anup Engineering - ICICI Securities

RBI OMO announcement of Rs. 10000 crore - Angel Broking

TCS deal win - Sep 24, 2020 - Angel Broking

View on Pre-Monetary Policy by Upasna Bhardwaj, Senior Economist at Kotak Mahindra Bank

US FDA approval to Zydus Cadila - Angel Broking

HDFC Securities Institutional Research Desk: Cement Sector Thematic - Spotting the sweet spot

Bharat Forge - Expectation hurdle remains steep - ICICI Securities

Auto

Mutual Fund Review - September, 2020 - ICICI Securities

UTI AMC announces IPO date - Angel Broking

Asian Paints - Mr. Amarjeet Maurya - AVP - Mid Caps, Angel Broking Ltd

Britannia Industries - Mr. Amarjeet Maurya - AVP - Mid Caps, Angel Broking Ltd

Hexaware Technologies (Not Rated): Hexaware accepts 475/share as final delisting price - ICICI Securities

CAMS IPO - Day 2 Subscription - Angel Boking

Chemcon Speciality Chemicals - IPO subscribed 12.62 times on second day - Angel Broking

General insurance - Fire, health remain growth drivers, rising Covid claims a concern - ICICI Securities

Supreme Industries - Perfect recipe for rerating; upgrade to BUY - ICICI Securities

Titan Company - Best positioned to gain from faster-than-expected recovery. Upgrade to ADD - ICICI Securities

Sector Update - Telecom - Sep 23, 2020 - ICICI Securities

Allcargo Logistics - Highlights of Blackstone deal - ICICI Securities

I-direct Instinct - Gokaldas Exports

Economy: RBI's trilemma: allows for INR strength - Kotak

HCL Technologies - Company Update - ICICI Securities

Chemcon Speciality Chemicals - IPO Review - ICICI Securities

Angel Broking - IPO Note - YES Securities

TCS - Announcement of its blockhchain based solutions on Microsoft Azure - Angel Broking

Amber Enterpirses acquire Sidwal - Angel Broking

Dixon Technologies - Buy - YES Securities

HCL Technologies acquisition of DWS Limited - Angel Broking

Allcargo Logistics CFO Resignation - Angel Broking







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019